Antoine Magnan

Antoine Magnan

Auto-generated profile, based on publicly available information

Antoine Magnan

Hôpital Foch, Suresnes, France

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2022 in Allergy
Verified
Journal Article
Open access
PDF file
LCLuc Colas
Luc Colas
AMAntoine Magnan
Antoine Magnan
Sophie BrouardSophie Brouard
Sophie Brouard
Immunoglobulin E is the latest discovered of immunoglobulin family and has been long associated with anaphylaxis and worm expulsion. Immunoglobulin E, along with mast cells, basophils, and eosinophils, is also a hallmark of type 2 immunity which is dysregulated in numerous diseases such as asthma, rhinitis, atopic dermatitis, and eosinophilic esophagitis in addition to anaphylaxis as aforementioned. However, recent advances have shed light on IgE regulation and memory explaining the low level of free IgE, the scarcity of IgE plasma cells that are mainly short live and the absence of IgE memory B cells in homeostatic conditions. Furthermore, IgE was implicated in inflammatory conditions beyond allergic disorders where IgE‐mediated facilitated antigen presentation can enhance cellular and humoral response against autoantigens in systemic lupus or chronic urticaria leading to more severe disease and even against neoantigen facilitating tumor cell lysis. At last, IgE was unexpectedly associated with allograft rejection or atheromatous cardiovascular diseases where precise mechanisms remain to be deciphered. The purpose of this review is to summarize these recent advances in IgE regulation, biology, and physiopathology beyond allergic diseases opening whole new fields of IgE biology to explore.

7 October 2021 in Clinical & Experimental Allergy
Verified
Journal Article
Open access
PDF file
DHDorian Hassoun
Dorian Hassoun
Olivier MalardOlivier Malard
Olivier Malard
SBSebastien Barbarot
Sebastien Barbarot
AMAntoine Magnan
Antoine Magnan
LCLuc Colas
Luc Colas
Asthma, atopic dermatitis and chronic rhinoconjunctivitis are highly heterogeneous. However, epidemiologic associations exist between phenotypic groups of patients. Atopic march is one such association but is not the only common point. Indeed, beyond such phenotypes, hallmarks of type 2 immunity have been found in these diseases involving immune dysregulation as well as environmental triggers and epithelial dysfunction. From the canonical Th2 cytokines (IL‐4, IL‐5, IL‐13), new cellular and molecular actors arise, from the epithelium's alarmins to new innate immune cells. Their interactions are now better understood across the different environmental barriers, and slight differences appeared. In parallel, the development of type 2‐targeting biotherapies not only raised hope to treat those diseases but also raised new questions regarding their true pathophysiological involvement. Here, we review the place of type 2 immunity in the different phenotypes of asthma, chronic rhinitis, chronic rhinosinusitis and atopic dermatitis, highlighting nuances between them. New hypotheses rising from the use of biotherapies will be discussed along with the uncertainties and unmet needs of this field.

15 November 2022 in Journal of Asthma
Verified
Journal Article
Closed access
CMC. Menigoz
C. Menigoz
SDS. Dirou
S. Dirou
ACA. Chambellan
A. Chambellan
DHD. Hassoun
D. Hassoun
AMA. Moui
A. Moui
FBFrançois-Xavier Blanc
François-Xavier Blanc
Introduction: Severe eosinophilic asthma (SEA) is associated with multiple exacerbations. Fractional exhaled nitric oxide (FeNO), a biomarker of airway T2 inflammation, is known to be correlated with the risk of exacerbations. While the use of FeNO is well established to predict the therapeutic response to dupilumab (anti-IL-4/IL-13), it remains uncertain for biologics targeting the IL-5 pathway. Methods: We conducted an observational, retrospective, monocentric analysis of adults with SEA who started mepolizumab (anti-IL-5) or benralizumab (anti-IL-5-R) between January 1, 2016 and December 31, 2020. Results: Data were collected for 109 patients. All participants reported uncontrolled asthma with a median of 3 annual exacerbations and a median Asthma Control Test score of 12. They all had an initial blood eosinophilia >300/mm3, with a median at 610/mm3 (IQR 420-856). Patients with a baseline FeNO ≥50 ppb reported more exacerbations in the previous year than those with a FeNO <50 ppb (p = 0.02). After initiation of treatment, change in FeNO was not associated with therapeutic response. However, decrease in the annual number of exacerbations was significantly greater in patients with a baseline FeNO ≥50 ppb than in those with a baseline FeNO <50 ppb (-3.3 ± 2.7 vs -0.9 ± 2.4, respectively; p = 0.01). There was no association between baseline FeNO values and subsequent lung function, asthma control or reduction of oral corticosteroids use. Conclusion: In this real-world cohort, adults with SEA who had a baseline FeNO ≥50 ppb experienced a greater decrease in exacerbations after 12 months of anti-IL-5 or IL-5-R biologics than those with a FeNO <50 ppb.

1 May 2006 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
Emilie MamessierEmilie Mamessier
Emilie Mamessier
FMFrançois Milhe
François Milhe
MBMonique Badier
Monique Badier
PTPascal Alexandre Thomas
Pascal Alexandre Thomas
AMAntoine Magnan
Antoine Magnan
MRMartine Reynaud-Gaubert
Martine Reynaud-Gaubert

1 April 1997 in Clinical & Experimental Allergy
Verified
Journal Article
Closed access
AMA. Magnan
A. Magnan
FRfrederique Retornaz
frederique Retornaz
ATAnne Tsicopoulos
Anne Tsicopoulos
JBJ. Brisse
J. Brisse
DPD. VAN Pee
D. VAN Pee
DVD. Vervloet
D. Vervloet

1 January 2023 in Allergy, Asthma & Immunology Research
Verified
Journal Article
Open access
PDF file
EDEléonore Dijoux
Eléonore Dijoux
MKMartin Klein
Martin Klein
BMBarbara Misme-Aucouturier
Barbara Misme-Aucouturier
MCMarie-Aude Cheminant
Marie-Aude Cheminant
MCMarion de Carvalho
Marion de Carvalho
GBGregory Bouchaud
Gregory Bouchaud
Dijoux E, et al. Allergy Asthma Immunol Res. 2023 Mar;15(2):246-261. https://doi.org/10.4168/aair.2023.15.2.246